Technical Analysis for EYPT - EyePoint Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 1.87 3.89% 0.07
EYPT closed up 3.89 percent on Friday, September 13, 2019, on 3.06 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical EYPT trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%

Older signals for EYPT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. In addition, the company has developed DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. Further, it develops YUTIQ shorter-actinguveitis for the treatment of posterior segment uveitis; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Additionally, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It sells its products primarily in the United States and Europe. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, and Enigma Therapeutics Limited. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Medicine Chemistry Biopharmaceutical Organic Compounds Technology Platforms Wet Age Related Macular Degeneration Glucocorticoids Macular Edema Ophthalmic Products Uveitis Chronic Diseases Diabetic Macular Edema Eye Diseases Pregnanes Alimera Sciences Cytomegalovirus Retinitis Diketones Diols
Is EYPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.94
52 Week Low 1.19
Average Volume 302,146
200-Day Moving Average 1.8856
50-Day Moving Average 1.4694
20-Day Moving Average 1.5145
10-Day Moving Average 1.577
Average True Range 0.0944
ADX 30.58
+DI 44.7147
-DI 9.4264
Chandelier Exit (Long, 3 ATRs ) 1.6369
Chandelier Exit (Short, 3 ATRs ) 1.6032
Upper Bollinger Band 1.7511
Lower Bollinger Band 1.2779
Percent B (%b) 1.25
BandWidth 31.244635
MACD Line 0.0739
MACD Signal Line 0.0313
MACD Histogram 0.0427
Fundamentals Value
Market Cap 73.62 Million
Num Shares 39.4 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -3.60
Price-to-Sales 6.21
Price-to-Book 3.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.10
Resistance 3 (R3) 2.09 2.00 2.06
Resistance 2 (R2) 2.00 1.95 2.01 2.05
Resistance 1 (R1) 1.94 1.91 1.97 1.95 2.03
Pivot Point 1.85 1.85 1.87 1.86 1.85
Support 1 (S1) 1.79 1.80 1.82 1.79 1.71
Support 2 (S2) 1.70 1.76 1.71 1.69
Support 3 (S3) 1.64 1.70 1.68
Support 4 (S4) 1.64